Your answers will help us provide you with the most helpful information about REBYOTA™.
Discover how REBYOTA offers hope in the prevention of recurrent C. diff.
If you’re ready to talk to a doctor, this
customized discussion guide is a great way
REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals
18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.
Please click to see the full Prescribing Information
The link you have selected will direct you to a site or resource outside of our website.